AzTrials
AzTrials

Knee ArthroscopyPhase 3CHLORODEXNCT07674576

Efficacy of Intravenous Dexamethasone in Prolonging the Duration of Spinal Anesthesia With Chloroprocaine in Knee Arthroscopy

A Phase 3 study testing Sodium Chloride 0.9%, Dexamethasone and Chloroprocaine Injection [Clorotekal] in people with Knee Arthroscopy, run by CMC Ambroise Paré at 1 site in France.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Chloroprocaine is a short-acting local anesthetic that allows rapid recovery and early ambulation but is currently recommended for procedures lasting 40 minutes or less. Dexamethasone is commonly used during anesthesia for the prevention of postoperative nausea and vomiting and has also been shown to prolong the… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Knee Arthroscopy
What is being tested?
Sodium Chloride 0.9%, Dexamethasone and Chloroprocaine Injection [Clorotekal]
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
60 participants
Where
1 siteFrance
Study dates
1 Sep 2026to 1 Sep 2028
Phase
Phase 3
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Undergoing knee arthroscopy lasting ≤ 40 minutes requiring spinal anesthesia (diagnostic arthroscopy or meniscal surgery),
  • Signed written informed consent form,
  • Affiliation to a social security system,
  • Negative pregnancy test on the day of procedure for non-menopausal patients.

Who cannot join

  • Contraindications to spinal anesthesia with intrathecal chloroprocaine
  • History of diabetes,
  • Pre-existing peripheral neuropathy,
  • American Society of Anesthesiologists (ASA) physical status IV,
  • Contraindication to dexamethasone,
  • Hypersensitivity of any drug used in this study,
Show all 16Show fewer
  • Long-term oral corticosteroid therapy,
  • Chronic opioid use,
  • Chronic pain syndromes,
  • Contraindications to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) (Ketoprofen, Celecoxib)
  • Need for a peripheral nerve block in addition to spinal anesthesia (e.g. knee ligamentoplasty),
  • Mental or linguistic inability to understand the study,
  • Patients under legal protection (guardianship, curatorship or safeguard of justice),
  • Patients currently included or planning to be included in another interventional study,
  • Pregnant or breastfeeding women,
  • Women of childbearing potential not using effective contraception.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Sébastien BLOC, MD contact

01 44 14 11 11

sebebloc@gmail.com

France1 site
  • Clinique Drouot Rémusat

    Paris, Île-de-France Region, 75016

    Cyril QUEMENEUR, MD, 01 44 14 11 11, c.quemeneur@gmx.com

Other trials in France

About this study

Official title: Efficacy of Intravenous Dexamethasone in Prolonging the Duration of Spinal Anesthesia With Chloroprocaine in Knee Arthroscopy: a Double-blind, Randomized, Controlled Trial

Chloroprocaine is a short-acting local anesthetic that allows rapid recovery and early ambulation but is currently recommended for procedures lasting 40 minutes or less.

Dexamethasone is commonly used during anesthesia for the prevention of postoperative nausea and vomiting and has also been shown to prolong the duration of analgesia and sensory block after regional anesthesia.

Read more

Dexamethasone may therefore extend the duration of chloroprocaine spinal anesthesia, potentially allowing its use for longer surgical procedures while maintaining the benefits of rapid postoperative recovery.

This study aims to evaluate whether intravenous dexamethasone can prolong the effects of spinal anesthesia performed with chloroprocaine in adults undergoing knee arthroscopy.

Read the detailed description

This is a monocenter, prospective, randomized (1:1 ratio), controlled, parallel-group, double-blind, phase III superiority trial assessing the efficacy and the safety of IV dexamethasone for prolonging sensory block in patients undergoing knee arthroscopy under spinal anesthesia with chloroprocaine.

Participants will be randomly allocated into two groups:

  • Group CHLORO (control group): Patients will receive spinal anesthesia with chloroprocaine 40mg (Clorotekal®10 mg/mL, solution for injection, 4 mL) combined with an IV infusion of 3 mL of normal saline solution diluted in 100 mL of 0.9% sodium chloride, administered over 20 minutes.
  • Group CHLORODEX (experimental group): Patients will receive spinal anesthesia with chloroprocaine 40 mg (Clorotekal®10 mg/mL, solution for injection, 4 mL) combined with an IV infusion of dexamethasone at a dose of 0.15 mg/Kg (maximum 16 mg), diluted in 100 mL of 0.9% sodium chloride, administered over 20 minutes.

To ensure blinding, study infusions (saline or dexamethasone) will be prepared in identical 100 mL bags and labelled by a pharmacy staff member or an "outside protocol" healthcare professional (physician or nurse) not involved in patient care or assessment.

The infusion will start approximately 10-15 minutes before the spinal punction.

In the operating room, patients will receive standard perioperative care for spinal anesthesia, including placement of a peripheral intravenous line, supplemental low-flow oxygen therapy to maintain SpO₂ > 93%, continuous hemodynamic monitoring, and strict aseptic precautions. Analgesic premedication with paracetamol combined with either ketoprofen or celecoxib will be administered according to institutional practice.

Spinal anesthesia will be performed with the patient in a semi-sitting position via the L3-L4 or L4-L5 interspace using a 25G x 80mm Sprotte needle. After cerebrospinal fluid reflux, 40 mg of chloroprocaine without adjuvant will be injected intrathecally, and patients will then be positioned in the supine position for the procedure.

Knee arthroscopy will be performed according to standard surgical practice, without any modification of the surgical procedure for study purposes.

No additional sedation or analgesia will be administered during the procedure. In the event of failure of spinal anesthesia or early recovery of sensation, conversion to general anesthesia or deep sedation may be performed at the discretion of the anesthesiologist, depending on the clinical situation.

Postoperatively, multimodal analgesia will be initiated according to the institutional protocol, combining paracetamol, nefopam, and either ketoprofen or celecoxib, with morphine administered if necessary.

Sensory and motor blocks will be assessed every 5 minutes after spinal puncture until regression of two dermatomes and then every 10 minutes until recovery of four dermatomes and complete motor function (maximum until hospital discharge).

Motor block will be assessed using the Bromage score and sensory block will be assessed using the Pin Prick test and the cold test.

The primary objective of the study is to evaluate the efficacy of intravenous dexamethasone in prolonging sensory block following spinal anesthesia with chloroprocaine, as assessed by the time from intrathecal injection to regression of sensory block by two dermatomes from the highest level of sensory block achieved, as measured by the pin-prick test.

Being tested
Sodium Chloride 0.9%, Dexamethasone, Chloroprocaine Injection [Clorotekal]
Keywords
Knee arthroscopy, dexamethasone, chloroprocaine, spinal anesthesia, sensory block, motor block

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Sodium Chloride 0.9%Drug

    IV infusion of 3 mL of normal saline solution diluted in 100 mL of 0.9% sodium chloride, administered over 20 minutes

  • DexamethasoneDrug

    IV infusion of dexamethasone at a dose of 0.15 mg/kg (maximum 16 mg), diluted in 100 mL of 0.9% sodium chloride, administered over 20 minutes

  • Chloroprocaine Injection [Clorotekal]Drug

    Spinal anesthesia with chloroprocaine 40 mg

Study groups in NCT07674576
Study groupRoleWhat they receive
CHLOROPlacebo comparatorNormal saline solution IV infusion
Receives: Drug: Sodium Chloride 0.9%; Drug: Chloroprocaine Injection [Clorotekal]
CHLORODEXExperimentalDexamethasone IV infusion
Receives: Drug: Dexamethasone; Drug: Chloroprocaine Injection [Clorotekal]

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Time to regression of sensory block by two dermatomes (pin-prick test)

    Time (in minutes) from the spinal puncture to the first assessment at which the sensory block has regressed by two dermatomes from the maximum (highest/most cephalad) dermatome level of sensory block achieved after the puncture, assessed with the pin-prick test. Sensory testing will be performed every 5 minutes until two-dermatome regression is observed. Responses will be recorded as: 2 = sharp (normal sensation), 1 = dull (decreased sensation), and 0 = absent sensation.

    Measured: Up to 2 hours following spinal anesthesia

Secondary outcomes (17)
  1. Time to complete resolution of motor block

    Time (in minutes) from the spinal puncture to complete recovery of motor block, assessed by the Modified Bromage Scale (0-3: 0 = full flexion of hip, knee, and ankle; 1 = inability to raise extended leg; 2 = inability to flex knee; 3 = no movement of hip, knee, or ankle). Motor block will be assessed every 5 minutes after the spinal puncture until regression of the sensory block by two dermatomes, and then every 10 minutes until complete motor recovery (Bromage 0).

    Measured: Up to 8 hours following spinal anesthesia

  2. Time to regression of sensory block by four dermatomes (pin-prick test)

    Time (in minutes) from the spinal puncture to regression of four dermatomes from the highest dermatome level of sensory block achieved after the puncture. Sensory block will be assessed using the pin-prick test every 5 minutes after the spinal puncture until regression by two dermatomes, and then every 10 minutes until regression by four dermatomes. Responses will be recorded as: 2 = sharp (normal sensation), 1 = dull (decreased sensation), and 0 = absent sensation.

    Measured: Up to 8 hours following spinal anesthesia

  3. Maximum sensory block level

    Highest dermatome level of sensory block achieved after the spinal puncture (pin-prick test).

    Measured: Up to 30 minutes following spinal anesthesia

  4. Time to maximum sensory block level

    Time (in minutes) from the spinal puncture to the highest blocked dermatome (pin-prick test).

    Measured: Up to 30 minutes following spinal anesthesia

  5. Need for additional anesthetic procedure

    Whether an additional anesthetic procedure was required during surgery, including sedation or conversion to general anesthesia

    Measured: From spinal anesthesia to the end of surgery

  6. Time to regression of sensory block by two dermatomes (cold test)

    Time (in minutes) from spinal puncture to two dermatome sensory regression assessed by a standardized cold test

    Measured: Up to 2 hours following spinal anesthesia

  7. Incidence of hypotension

    Any episode of hypotension, defined as a systolic blood pressure (SBP) < 90 mmHg and/or a mean arterial pressure (MAP) < 65 mmHg and/or a decrease in blood pressure ≥ 30% from baseline

    Measured: From spinal anesthesia to 24 hours after surgery

  8. Incidence of bradycardia

    Any episode of bradycardia defined as a heart rate (HR) < 50 bpm

    Measured: From spinal anesthesia to 24 hours after surgery

  9. Incidence of nausea

    Any episode of nausea reported by the patient or nursing team

    Measured: From spinal anesthesia to 24 hours after surgery

  10. Incidence of vomiting

    Any episode of vomiting reported by the patient or nursing team

    Measured: From spinal anesthesia to 24 hours after surgery

  11. Incidence of pruritus

    Any episode of pruritus reported by the patient or nursing team

    Measured: From spinal anesthesia to 24 hours after surgery

  12. Incidence of urinary retention

    Any episode of urinary retention reported by the patient or nursing team

    Measured: From spinal anesthesia to 24 hours after surgery

  13. Maximal pain score in the PACU

    Maximal pain score collected in the PACU using a Numeric Rating Scale (NRS-Pain) ranging from 0 to 10 (0= no pain; 10= extreme pain).

    Measured: Up to 6 hours following spinal anesthesia

  14. Total opioid consumption

    Total opioid consumption, converted to oral morphine equivalents (OME, mg) from the intraoperative period to 24 hours postoperatively, including opioid use at home as reported during the Day 1 follow-up

    Measured: From spinal anesthesia to 24 hours after surgery

  15. Pain intensity

    Pain intensity at rest and during movement will be assessed using a Numeric Rating Scale (NRS-Pain) ranging from 0 to 10 (0= no pain; 10= extreme pain). Pain scores will be recorded intraoperatively (H0)in the PACU (H1), during ambulatory hospitalization (H3 and H6), and at home until Day-1 (H9, H12 and H24).

    Measured: From spinal anesthesia to 24 hours after surgery

  16. Duration of surgery

    Time (in minutes) between the skin incision and the last suture

    Measured: Intraoperative period

  17. Incidence of post-puncture headache

    Any episode of headache reported by the patient or nursing team

    Measured: From spinal anesthesia to 24 hours after surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Jun 2026
  2. Study start1 Sep 2026 (estimated)
  3. Primary completion31 Aug 2028 (estimated)
  4. Study completion1 Sep 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07674576
Sponsor's protocol ID
2023/01
Other IDs
2023-505247-39-00, 2023
Acronym
CHLORODEX
Status last verified
Jun 2026
First submitted
19 Jun 2026
Last updated
29 Jun 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Sodium Chloride 0.9%, Dexamethasone and Chloroprocaine Injection [Clorotekal] in people with Knee Arthroscopy, run by CMC Ambroise Paré at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 29 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Sébastien BLOC, MD (01 44 14 11 11, sebebloc@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Time to regression of sensory block by two dermatomes (pin-prick test) (time frame: Up to 2 hours following spinal anesthesia). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jun 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in